A lentiviral vector pseudotype suitable for vaccine development

Journal of Gene Medicine

Volumn 13, Issue 3, 2011, Pages 181-187

  Lopes, Luciene ^a   Dewannieux, Marie ^b   Takeuchi, Yasuhiro ^a   Collins, Mary K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Lentiviral vector; Ross river virus; Vaccine

Indexed keywords

LENTIVIRUS VECTOR; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; ROSS RIVER ALPHA VIRUS; T LYMPHOCYTE; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS;

3T3 CELLS; ANIMALS; CELL LINE; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED C57BL; ROSS RIVER VIRUS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VACCINES, SYNTHETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; MUS; ROSS RIVER VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79955165554     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1553     Document Type: Article

References (38)

1. He Y, Zhang J, Donahue C, Falo LD Jr. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006; 24: 643-656.
2. Breckpot K, Escors D, Arce F, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010; 84: 5627-5636.
3. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003; 111: 1673-1681.
4. Palmowski MJ, Lopes L, Ikeda Y, et al. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004; 172: 1582-1587.
5. Rowe HM, Lopes L, Ikeda Y, et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 2006; 13: 310-319.
6. Dai B, Yang L, Yang H, et al. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009; 106: 20382-20387.
7. Loisel-Meyer S, Felizardo T, Mariotti J, et al. Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 2009; 8: 692-702.
8. Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008; 3: E3973.
9. Beignon AS, Mollier K, Liard C, et al. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 2009; 83: 10963-10974.
10. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
11. Bachrach HL, Callis JJ, Hess WR. The growth and cytopathogenicity of vesicular stomatitis virus in tissue culture. J Immunol 1955; 75: 186-191.
12. Hoffmann M, Wu YJ, Gerber M, et al. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. J Gen Virol 2010; 91: 2782-2783.
13. Ikeda Y, Takeuchi Y, Martin F, et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21: 569-572.
14. Strang BL, Takeuchi Y, Relander T, et al. Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J Virol 2005; 79: 1765-1771.
15. Strang BL, Ikeda Y, Cosset FL, Collins MK, Takeuchi Y. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther 2004; 11: 591-58.
16. Relander T, Johansson M, Olsson K, et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther 2005; 11: 452-459.
17. Takeuchi Y, Liong SH, Bieniasz PD, et al. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl (alpha1-3)galactosylation. J Virol 1997; 71: 6174-6178.
18. DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218-222.
19. Croyle MA, Callahan SM, Auricchio A, et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J Virol 2004; 78: 912-921.
20. Pichlmair A, Diebold SS, Gschmeissner S, et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 2007; 81: 539-547.
21. Noser JA, Towers GJ, Sakuma R, et al. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 2006; 80: 7769-7774.
22. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther 2009; 20: 554-562.
23. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
24. Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol Immunother 2006; 55: 1011-1016.
25. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
26. Sharkey CM, North CL, Kuhn RJ, Sanders DA. Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J Virol 2001; 75: 2653-2659.
27. Neil S, Martin F, Ikeda Y, Collins M. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 2001; 75: 5448-5456.
28. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 1993; 90: 3038-3042.
29. Lopes L, Dewannieux M, Gileadi U, et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008; 82: 86-95.
30. Arce F, Rowe H, Chain B, Lopes L, Collins MK. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunisation. Mol Ther 2009; 17: 1643-1650.
31. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 2002; 76: 1488-1495.
32. Escors D, Lopes L, Lin R, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008; 111: 3050-3061.
33. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
34. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
35. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
36. Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009; 1: 2ra4.
37. Pan D, Whitley CB. Closed hollow-fiber bioreactor: a new approach to retroviral vector production. J Gene Med 1999; 1: 433-440.
38. Ghani K, Garnier A, Coelho H, et al. Retroviral vector production using suspension-adapted 293GPG cells in a 3 l acoustic filter-based perfusion bioreactor. Biotechnol Bioeng 2006; 95: 653-660.